Positive Conclusion Reached in Immunomodulator I Patent Opposition Patent opposition hearing cancelled
Positive Conclusion Reached in Immunomodulator I Patent Opposition Patent opposition hearing cancelled
The FTSE AIM market has fallen in value by a third over the past five years, and 12% in 2023 alone.
Shares of AstraZeneca PLC (LSE: AZN) have witnessed a 2% increase, surpassing 11,100p for the first time in a month, following the company’s announcement of promising results from an ongoing
OptiBiotix Health plc (AIM: OPTI), a life sciences business developing compounds to tackle obesity, high cholesterol, diabetes and skincare, announces that it has reached agreement to launch its own brands
Notice of allowance for patent grant in Japan
Scancell Holdings PLC (AIM: SCLP, OTC: SCNLF) shares soared by 23% in early market hours after it reported that the initial phase of its phase II SCOPE trial for advanced
An important step in the continued protection of Poolbeg’s patent family
Successful Completion of ALS-6000-101 Sixth Dose Escalation and Clinical Update
Hemogenyx Pharmaceuticals Announces Strategic Investment from Prevail Partners, LLC
Significant progress made and well positioned for future growth
Strong first-half performance and record forward visibility Upgrade of Full Year Revenue and EBITDA Guidance